Zolk O

ORCID: 0000-0002-8220-3834 · 1 paper in corpus

2025

Safety, Tolerability, and Pharmacokinetics of Filapixant, a Highly Selective P2X3 Receptor Antagonist, in an Ascending-Single-Dose First-in-Human Study.

Pharmaceuticals (Basel, Switzerland) ·doi:10.3390/ph18050758

Background/Objectives: P2X3 receptor antagonists have been suggested as a potential treatment for urogenital, respiratory and pain conditions. This first-in-human (FiH) study evaluated filapixant, a new P2X3 receptor antagonist with high re…